Dr. Pecot Discusses T-VEC in Lung Cancer

Chad Pecot, MD
Published: Monday, Apr 02, 2018



Chad Pecot, MD, assistant professor, School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses talimogene laherparepvec (T-VEC; Imlygic) in the treatment of patients with lung cancer.

T-VEC is genetically engineered from herpes to replicate preferentially inside cancer cells without giving the pathogenic disease. Pecot says that the idea is that it will lyce cancer cells once it replicates inside of them. It also produces a protein called GM-CSF, and what that will do is recruit a lot of immune cells to the tumor.

In lycing the tumor, T-VEC presents antigens from the tumor to the immune system, and secretes the protein GM-CSF in combination with immunotherapy. T-VEC plus immunotherapy has shown impressive response rates in melanoma, making the potential for the combination in lung cancer grow.


Chad Pecot, MD, assistant professor, School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses talimogene laherparepvec (T-VEC; Imlygic) in the treatment of patients with lung cancer.

T-VEC is genetically engineered from herpes to replicate preferentially inside cancer cells without giving the pathogenic disease. Pecot says that the idea is that it will lyce cancer cells once it replicates inside of them. It also produces a protein called GM-CSF, and what that will do is recruit a lot of immune cells to the tumor.

In lycing the tumor, T-VEC presents antigens from the tumor to the immune system, and secretes the protein GM-CSF in combination with immunotherapy. T-VEC plus immunotherapy has shown impressive response rates in melanoma, making the potential for the combination in lung cancer grow.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x